MMRF Interactions with Industry

Mary DeRome
Translational Research Manager
deromem@themmrf.org
Multiple myeloma is the second most prevalent blood cancer, and has no cure. How do we form and maintain a relationship with our pharma industry partners, to the benefit of our patients?

**What’s in it for us?**

- Grant funding to support young investigator grant programs
- Grant funding to support patient/caregiver and clinical (CME) education
- Grant funding to support several research roundtables yearly
- Clinical trial support (12 year, $40 million longitudinal CoMMpass study)
- Support and collaboration for translational research projects
- Support and collaboration for Ph I/IIb clinical trials in our clinical Consortium

**What’s in it for them?**

- Significant ROI...
Interactions with Industry:
MMRF CoMMpass trial

- CoMMpass is a $40 million dollar study of 1000+ patients over 8 years
- all clinical data, and genomic profiling at diagnosis and each relapse (CLIA)
- Pharma partners finance half of the cost
- Data is freely available to researchers at non-profit institutions
- ROI for pharma:
  - First and best access to CoMMpass data – 6 month embargo in place
  - Yearly meetings with MM KOLs (“CoMMpass Data Jamboree”) to brainstorm on new analyses of data and discuss collaboration on new studies
MMRC: Consortium of 22 leading academic clinical sites, founded in 2004

IST and CST trials (PhI/IIb) are run through the MMRC - to date 69 total trials, 36 compounds, jointly funded MMRF/pharma

What do we offer?
Fast trial start-up
Fast patient recruitment
Access to KOLs for trial proposals

Days to Open

55 of 72 total patients from MMRC
Interactions with Industry:
MMRF Translational Initiatives

MMRF initiates and guides collaboration between pharma partners and academic labs for translational studies: testing of new compounds using banked patient samples, and in novel MM cell and animal models.
Thank you!